Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Open Label Study to Assess the Efficacy and Safety of the Intravenous and Oral Ibandronic Acid for Improving the Performance Status of Patients With Malignant Bone Disease Secondary to Solid Tumors and Hematological Malignancies

NCT02561039 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT02561039
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02561039 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Open Label Study to Assess the Efficacy and Safety of the Intravenous and Oral Ibandronic Acid for Improving the Performance Status of Patients With Malignant Bone Disease Secondary to Solid Tumors and Hematological Malignancies
Lead sponsor
Hoffmann-La Roche
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2006
Completion date
March 31, 2008
Enrollment
97 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

pain; bone neoplasms; neoplasm metastasis